{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-019103","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2023-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.058620+00:00","generated_at":"2026-06-20T06:38:53.647210+00:00","sec_items":["2.02","2.05","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Quince Therapeutics cuts workforce 47%; reports $94M cash; pivots to in-licensing","bullets":["Preliminary unaudited cash, cash equivalents, and marketable securities of ~$94M as of Dec 31, 2022.","Board approved cost reduction plan cutting headcount by ~47%, expected to save ~$9.5M in annual operating expenses (2023).","Estimated restructuring costs of $0.6M–$0.8M; workforce reduction begins Feb 2023, completes by Apr 2023.","Company to prioritize in-licensing and acquisition of clinical-stage assets for rare diseases; out-license bone-targeting platform NOV004.","Out-licensing of NOV004 to commence immediately; goal to conclude partnership by end of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-019103","json":"https://secwatch.observer/filing/0001193125-23-019103.json","markdown":"https://secwatch.observer/filing/0001193125-23-019103.md","text":"https://secwatch.observer/filing/0001193125-23-019103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523019103/0001193125-23-019103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523019103/d442243d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T06:38:53.647210+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fb42c1e6b6e385d67ca3630af8b6aeb45b25e93d","claim":"Quince Therapeutics, Inc. reported preliminary financial results for the fourth quarter and year ended December 31, 2022.","evidence_excerpt":"The Company also reported on a preliminary and unaudited basis its estimated cash, cash equivalents, and marketable securities of approximately $94 million as of December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523019103/0001193125-23-019103-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"f8c8146cff7f0bd3ca1cad5e4c42c24a0e6b09cb","claim":"Quince Therapeutics, Inc. announced a restructuring with charges of approximately $0.6 million to $0.8 million (approximately 47%).","evidence_excerpt":"share-based compensation and any one-time costs related to strategic actions). In connection with the Plan, the Company estimates that it will incur expenses of approximately $0.6 million to $0.8 million, substantially all of which will be cash expenditures and other costs relating to the Plan through August 2023. The Company may incur other charges, including","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523019103/0001193125-23-019103-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $0.6 million to $0.8 million"},{"label":"Headcount","value":"approximately 47%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}